* The Phase I PERFORM trial, taking place at four clinical trial centers across the U.S., will ev...
* XPOVIO® (selinexor) is the first and only exportin 1 (XPO1) inhibitor approved in Macau. * X...
* Clinical programs, including ATG-101 (PD-L1/4-1BB bispecific antibody), ATG-022 (Claudin 18.2 a...
* During the event, Antengene will review promising data of its R&D pipeline, includingATG-031 (a...
SHANGHAI and HONG KONG, Nov. 1, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...
SHANGHAI and HONG KONG, Sept. 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...
- The Phase I "PERFORM" study will evaluate the safety and tolerability, pharmacology, immunogenici...
SHANGHAI and HONG KONG, Aug. 25, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SE...
- Antengene and Hansoh Pharma to enter into collaboration agreement involving commercializatio...
- ATG-017 is an oral, potent and selective small molecule ERK1/2 inhibitor. Antengene has exclusiv...
* XPOVIO® (selinexor) is the first and only XPO1 inhibitor approved in Hong Kong * XPOVIO® has ...
- XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor...
* The TORCH-2 study is a Phase I/II trial of the mTORC1/2 inhibitor ATG-008 plus the Anti-PD-1 mo...
SHANGHAI and HONG KONG, May 23, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...
* ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibod...
- ATG-031, discovered and developed in-house by Antengene, is the world's first anti-CD24 antibody...
SHANGHAI and HONG KONG, May 17, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...
SHANGHAI and HONG KONG, April 27, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...
* Five posters showcased progress with multiple preclinical and clinical programs, includingATG-0...
* Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugat...